Efficacy and Safety of Topical Bimatoprost Solution 0.03% in Stable Vitiligo:A Preliminary Study View Homepage


Ontology type: schema:MedicalStudy     


Clinical Trial Info

YEARS

2010-2010

ABSTRACT

Vitiligo is an acquired depigmentation disorder of great cosmetic importance, affecting 1-4% of the world's population. Phototherapy and topical agents such as corticosteroids, calcineurin inhibitors, and vitamin-D derivatives are basic treatment modalities have been used in vitiligo but there is still no effective and safe treatment for this disease. Resistance to therapy, treatment complications and recurrence after treatment are the major problems of the current treatments. There are no clinical studies of use of Bimatoprost in treatment of vitiligo, as it is supposed to cause more hyperpigmentation and hypertrichosis as compared to other topical prostaglandin analogues; hence, the investigators decided to use it in treatment of localized vitiligo. Detailed Description Vitiligo is an acquired depigmentation disorder of great cosmetic importance, affecting 1-4% of the world's population. Vitiligo does not cause physical symptoms but because of its unsightly appearance, particularly on dark or tanned skin it can have considerable impact both psychologically and socially. Many ways of restoring normal colour to the skin have been tried but improvement is usually short-lived. The causes of vitiligo are not yet clearly understood, so many treatments have been developed on the basis of limited scientific evidence. There is no cure, and no way of limiting the spread of the disease has so far been found. The pathogenetic basis of the disease is melanocyte disappearance from achromic patches and experimental evidence has shown that three possible mechanisms enable this to occur: an apoptotic process, a necrotic event, and melanocythoragy following trauma due to impaired function of cell-cell or cell-matrix adhesion. Prostaglandins (PGs) are biologically active derivatives of 20 carbon atom polyunsaturated essential fatty acids released from cell membrane phospholipids. PGE2 and PGF2 are primary PGs. PGE2 is synthesized in skin and affects keratinocytes, Langerhans cells and melanocytes and regulates melanocyte proliferation. Epidermal melanocytes synthesize melanin in response to ultraviolet radiation (UVR). The mechanisms mediating the UVR-induced activation of melanogenesis are unknown but, as UVR induces the turnover of membrane phospholipids generating prostaglandins (PGs) and other products, it is possible that one of these might provide the activating signal. 1 In an in vitro study by Tomita et al .,2 normal human epidermal melanocytes became swollen and more dendritic when they were cultured with prostaglandin E 2 (PGE 2), but not with PGE 1. In another study by Nordlund et al ., 3 PGE2 applied topically to mice skin caused an increase in melanocyte density. Histologic studies indicate that PGE 2 also enhances melanogenesis. Recently, there have been many reports of iris darkening, hyperpigmentation of the eyelashes, and periocular hyperpigmentation induced by latanoprost . (prostaglandin F 2 α , used for the treatment of glaucoma). 4,5 Although the exact mechanism of this pigmentation is not clear, different mechanisms of the induction of hyperpigmentation by prostaglandins have been suggested, including: (i) influencing the responsiveness of melanocytes to neuronal stimuli; (ii) causing melanocyte proliferation; and (iii) a direct or second messenger mediated interaction with melanocytes via the stimulation of tyrosinase activity. Phototherapy and topical agents such as corticosteroids, calcineurin inhibitors, and vitamin-D derivatives are basic treatment modalities have been used in vitiligo but there is still no effective and safe treatment for this disease. Resistance to therapy, treatment complications and recurrence after treatment are the major problems of the current treatments. There are no clinical studies of use of Bimatoprost 0.03% in treatment of vitiligo, as it is supposed to cause more hyperpigmentation and hypertrichosis as compared to other topical prostaglandin analogues, hence, we decided to use it in treatment of localized vitiligo. Aim: In this study, twenty patients with vitiligo will be treated with topical Bimatoprost o.o3% ophthalmic solution for 4 months to elucidate its efficacy and tolerability in stable vitiligo. Patients and methods In this prospective, interventional, non-randomised, single blind, controlled study, twenty patients with stable vitiligo will be enrolled from the Dermatology out patient department of Gian Sagar Medical College and Hospital. The protocol will follow the Declaration of Helsinki and prior approval of Institutional Review Board will be obtained. Informed consent will be obtained from all patients. Detailed history and physical examination will be obtained. The age, sex, previous treatments, family history, type of vitiligo, durations of disease (in month), areas of involvement, Koebner phenomenon, leukotrichia will be recorded in special data sheet. The diagnosis of vitiligo will be made clinically. No concomitant treatment will be allowed and a washout period of at least 1 month will be given in patients using other therapies. Patients will be instructed to apply a Bimatoprost 0.03% solution twice daily to the depigmented skin taking care of no spillage to surrounding skin. The dimensions of the treated lesions will be measured in transverse and longitudinal axes at the time of enrollment, subsequently every month till 4 months. The measurement of the lesions will be performed by an independent observer who is blind to the treatment options. Photography will be done using a digital camera (Sony Digital Still Camera Cyber-shot ModelNO DSCF 717, Tokyo, Japan) at the baseline and at every follow up visit. Patients will be evaluated by the same observer who was blind to the treatment options. Primary Outcome Measures: The percentage of repigmentation in the previously depigmented patch, in form of color or size changes and folliculocentric repigmentation, of the treated and the control patches.6 Depending on the extent of repigmentation, the response to the treatment will be graded as: - no and minimal (<25%), - moderate (25-49%), - marked (50-74%), - excellent (75-99%), and - complete (100%) response. Response without reduction of the surface and only with perifollicular hyperpigmentation will be categorized as perifollicular pigmentation. Responding lesions will be defined as patches that achieved more than 50% repigmentation as compared with the baseline. Treatment will be discontinued if patients did not show any improvement or worsening at 2 months. More... »

URL

https://clinicaltrials.gov/show/NCT01202513

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/3053", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "type": "DefinedTerm"
      }
    ], 
    "description": "Vitiligo is an acquired depigmentation disorder of great cosmetic importance, affecting 1-4% of the world's population. Phototherapy and topical agents such as corticosteroids, calcineurin inhibitors, and vitamin-D derivatives are basic treatment modalities have been used in vitiligo but there is still no effective and safe treatment for this disease. Resistance to therapy, treatment complications and recurrence after treatment are the major problems of the current treatments. There are no clinical studies of use of Bimatoprost in treatment of vitiligo, as it is supposed to cause more hyperpigmentation and hypertrichosis as compared to other topical prostaglandin analogues; hence, the investigators decided to use it in treatment of localized vitiligo.\n\nDetailed Description\nVitiligo is an acquired depigmentation disorder of great cosmetic importance, affecting 1-4% of the world's population. Vitiligo does not cause physical symptoms but because of its unsightly appearance, particularly on dark or tanned skin it can have considerable impact both psychologically and socially. Many ways of restoring normal colour to the skin have been tried but improvement is usually short-lived. The causes of vitiligo are not yet clearly understood, so many treatments have been developed on the basis of limited scientific evidence. There is no cure, and no way of limiting the spread of the disease has so far been found. The pathogenetic basis of the disease is melanocyte disappearance from achromic patches and experimental evidence has shown that three possible mechanisms enable this to occur: an apoptotic process, a necrotic event, and melanocythoragy following trauma due to impaired function of cell-cell or cell-matrix adhesion. Prostaglandins (PGs) are biologically active derivatives of 20 carbon atom polyunsaturated essential fatty acids released from cell membrane phospholipids. PGE2 and PGF2 are primary PGs. PGE2 is synthesized in skin and affects keratinocytes, Langerhans cells and melanocytes and regulates melanocyte proliferation. Epidermal melanocytes synthesize melanin in response to ultraviolet radiation (UVR). The mechanisms mediating the UVR-induced activation of melanogenesis are unknown but, as UVR induces the turnover of membrane phospholipids generating prostaglandins (PGs) and other products, it is possible that one of these might provide the activating signal. 1 In an in vitro study by Tomita et al .,2 normal human epidermal melanocytes became swollen and more dendritic when they were cultured with prostaglandin E 2 (PGE 2), but not with PGE 1. In another study by Nordlund et al ., 3 PGE2 applied topically to mice skin caused an increase in melanocyte density. Histologic studies indicate that PGE 2 also enhances melanogenesis. Recently, there have been many reports of iris darkening, hyperpigmentation of the eyelashes, and periocular hyperpigmentation induced by latanoprost . (prostaglandin F 2 \u03b1 , used for the treatment of glaucoma). 4,5 Although the exact mechanism of this pigmentation is not clear, different mechanisms of the induction of hyperpigmentation by prostaglandins have been suggested, including: (i) influencing the responsiveness of melanocytes to neuronal stimuli; (ii) causing melanocyte proliferation; and (iii) a direct or second messenger mediated interaction with melanocytes via the stimulation of tyrosinase activity. Phototherapy and topical agents such as corticosteroids, calcineurin inhibitors, and vitamin-D derivatives are basic treatment modalities have been used in vitiligo but there is still no effective and safe treatment for this disease. Resistance to therapy, treatment complications and recurrence after treatment are the major problems of the current treatments. There are no clinical studies of use of Bimatoprost 0.03% in treatment of vitiligo, as it is supposed to cause more hyperpigmentation and hypertrichosis as compared to other topical prostaglandin analogues, hence, we decided to use it in treatment of localized vitiligo. Aim: In this study, twenty patients with vitiligo will be treated with topical Bimatoprost o.o3% ophthalmic solution for 4 months to elucidate its efficacy and tolerability in stable vitiligo. Patients and methods In this prospective, interventional, non-randomised, single blind, controlled study, twenty patients with stable vitiligo will be enrolled from the Dermatology out patient department of Gian Sagar Medical College and Hospital. The protocol will follow the Declaration of Helsinki and prior approval of Institutional Review Board will be obtained. Informed consent will be obtained from all patients. Detailed history and physical examination will be obtained. The age, sex, previous treatments, family history, type of vitiligo, durations of disease (in month), areas of involvement, Koebner phenomenon, leukotrichia will be recorded in special data sheet. The diagnosis of vitiligo will be made clinically. No concomitant treatment will be allowed and a washout period of at least 1 month will be given in patients using other therapies. Patients will be instructed to apply a Bimatoprost 0.03% solution twice daily to the depigmented skin taking care of no spillage to surrounding skin. The dimensions of the treated lesions will be measured in transverse and longitudinal axes at the time of enrollment, subsequently every month till 4 months. The measurement of the lesions will be performed by an independent observer who is blind to the treatment options. Photography will be done using a digital camera (Sony Digital Still Camera Cyber-shot ModelNO DSCF 717, Tokyo, Japan) at the baseline and at every follow up visit. Patients will be evaluated by the same observer who was blind to the treatment options. Primary Outcome Measures: The percentage of repigmentation in the previously depigmented patch, in form of color or size changes and folliculocentric repigmentation, of the treated and the control patches.6 Depending on the extent of repigmentation, the response to the treatment will be graded as: - no and minimal (<25%), - moderate (25-49%), - marked (50-74%), - excellent (75-99%), and - complete (100%) response. Response without reduction of the surface and only with perifollicular hyperpigmentation will be categorized as perifollicular pigmentation. Responding lesions will be defined as patches that achieved more than 50% repigmentation as compared with the baseline. Treatment will be discontinued if patients did not show any improvement or worsening at 2 months.", 
    "endDate": "2010-11-01T00:00:00Z", 
    "id": "sg:clinicaltrial.NCT01202513", 
    "keywords": [
      "efficacy", 
      "safety", 
      "solution", 
      "vitiligo", 
      "preliminary study", 
      "disorder", 
      "cosmetic", 
      "world", 
      "population", 
      "phototherapy", 
      "topical agent", 
      "corticosteroid", 
      "calcineurin inhibitor", 
      "derivative", 
      "treatment modality", 
      "effective and safe treatment", 
      "disease", 
      "resistance", 
      "therapy", 
      "treatment complication", 
      "Recurrence", 
      "major problem", 
      "current treatment", 
      "clinical study", 
      "prostaglandin", 
      "physical symptom", 
      "appearance", 
      "dark", 
      "considerable impact", 
      "color", 
      "skin", 
      "improvement", 
      "scientific evidence", 
      "disappearance", 
      "patch", 
      "experimental evidence", 
      "possible mechanism", 
      "apoptotic process", 
      "Wound and Injury", 
      "impaired function", 
      "cell-matrix adhesion", 
      "PG", 
      "active derivative", 
      "essential fatty acid", 
      "membrane phospholipid", 
      "Dinoprostone", 
      "keratinocytes", 
      "Langerhans cell", 
      "melanocyte", 
      "proliferation", 
      "epidermal melanocyte", 
      "melanin", 
      "ultraviolet radiation", 
      "melanogenesis", 
      "product", 
      "signal", 
      "vitro study", 
      "swollen", 
      "PGE-2", 
      "mouse skin", 
      "histologic study", 
      "iris", 
      "Prostaglandin F", 
      "glaucoma", 
      "exact mechanism", 
      "pigmentation", 
      "different mechanism", 
      "induction", 
      "responsiveness", 
      "stimulus", 
      "mediated interaction", 
      "stimulation", 
      "patient", 
      "tolerability", 
      "method", 
      "controlled study", 
      "dermatology", 
      "Medical College", 
      "protocol", 
      "declaration", 
      "approval", 
      "Research Ethic Committee", 
      "informed consent", 
      "history", 
      "physical examination", 
      "age", 
      "sex", 
      "previous treatment", 
      "family history", 
      "duration", 
      "involvement", 
      "phenomenon", 
      "data sheet", 
      "diagnosis", 
      "washout period", 
      "care", 
      "spillage", 
      "dimension", 
      "lesion", 
      "transverse", 
      "ax", 
      "enrollment", 
      "measurement", 
      "observer", 
      "treatment option", 
      "photography", 
      "digital camera", 
      "camera", 
      "Tokyo", 
      "Japan", 
      "baseline", 
      "primary outcome measure", 
      "size change", 
      "control", 
      "reduction", 
      "surface"
    ], 
    "name": "Efficacy and Safety of Topical Bimatoprost Solution 0.03% in Stable Vitiligo:A Preliminary Study", 
    "sameAs": [
      "https://app.dimensions.ai/details/clinical_trial/NCT01202513"
    ], 
    "sdDataset": "clinical_trials", 
    "sdDatePublished": "2019-03-07T15:23", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "file:///pack/app/us_ct_data_00009.json", 
    "sponsor": [
      {
        "id": "https://www.grid.ac/institutes/grid.464843.9", 
        "type": "Organization"
      }
    ], 
    "startDate": "2010-08-01T00:00:00Z", 
    "subjectOf": [
      {
        "id": "https://doi.org/10.1034/j.1600-0749.2000.130305.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1002467129"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/jcp.1041420216", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1004449106"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1111/1523-1747.ep12471536", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1015013193", 
          "https://doi.org/10.1111/1523-1747.ep12471536"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.jaad.2004.02.028", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1039256867"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1111/1523-1747.ep12285717", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1046751484", 
          "https://doi.org/10.1111/1523-1747.ep12285717"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1074797281", 
        "type": "CreativeWork"
      }
    ], 
    "type": "MedicalStudy", 
    "url": "https://clinicaltrials.gov/show/NCT01202513"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/clinicaltrial.NCT01202513'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/clinicaltrial.NCT01202513'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/clinicaltrial.NCT01202513'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/clinicaltrial.NCT01202513'


 

This table displays all metadata directly associated to this object as RDF triples.

154 TRIPLES      16 PREDICATES      137 URIs      125 LITERALS      1 BLANK NODES

Subject Predicate Object
1 sg:clinicaltrial.NCT01202513 schema:about anzsrc-for:3053
2 schema:description Vitiligo is an acquired depigmentation disorder of great cosmetic importance, affecting 1-4% of the world's population. Phototherapy and topical agents such as corticosteroids, calcineurin inhibitors, and vitamin-D derivatives are basic treatment modalities have been used in vitiligo but there is still no effective and safe treatment for this disease. Resistance to therapy, treatment complications and recurrence after treatment are the major problems of the current treatments. There are no clinical studies of use of Bimatoprost in treatment of vitiligo, as it is supposed to cause more hyperpigmentation and hypertrichosis as compared to other topical prostaglandin analogues; hence, the investigators decided to use it in treatment of localized vitiligo. Detailed Description Vitiligo is an acquired depigmentation disorder of great cosmetic importance, affecting 1-4% of the world's population. Vitiligo does not cause physical symptoms but because of its unsightly appearance, particularly on dark or tanned skin it can have considerable impact both psychologically and socially. Many ways of restoring normal colour to the skin have been tried but improvement is usually short-lived. The causes of vitiligo are not yet clearly understood, so many treatments have been developed on the basis of limited scientific evidence. There is no cure, and no way of limiting the spread of the disease has so far been found. The pathogenetic basis of the disease is melanocyte disappearance from achromic patches and experimental evidence has shown that three possible mechanisms enable this to occur: an apoptotic process, a necrotic event, and melanocythoragy following trauma due to impaired function of cell-cell or cell-matrix adhesion. Prostaglandins (PGs) are biologically active derivatives of 20 carbon atom polyunsaturated essential fatty acids released from cell membrane phospholipids. PGE2 and PGF2 are primary PGs. PGE2 is synthesized in skin and affects keratinocytes, Langerhans cells and melanocytes and regulates melanocyte proliferation. Epidermal melanocytes synthesize melanin in response to ultraviolet radiation (UVR). The mechanisms mediating the UVR-induced activation of melanogenesis are unknown but, as UVR induces the turnover of membrane phospholipids generating prostaglandins (PGs) and other products, it is possible that one of these might provide the activating signal. 1 In an in vitro study by Tomita et al .,2 normal human epidermal melanocytes became swollen and more dendritic when they were cultured with prostaglandin E 2 (PGE 2), but not with PGE 1. In another study by Nordlund et al ., 3 PGE2 applied topically to mice skin caused an increase in melanocyte density. Histologic studies indicate that PGE 2 also enhances melanogenesis. Recently, there have been many reports of iris darkening, hyperpigmentation of the eyelashes, and periocular hyperpigmentation induced by latanoprost . (prostaglandin F 2 α , used for the treatment of glaucoma). 4,5 Although the exact mechanism of this pigmentation is not clear, different mechanisms of the induction of hyperpigmentation by prostaglandins have been suggested, including: (i) influencing the responsiveness of melanocytes to neuronal stimuli; (ii) causing melanocyte proliferation; and (iii) a direct or second messenger mediated interaction with melanocytes via the stimulation of tyrosinase activity. Phototherapy and topical agents such as corticosteroids, calcineurin inhibitors, and vitamin-D derivatives are basic treatment modalities have been used in vitiligo but there is still no effective and safe treatment for this disease. Resistance to therapy, treatment complications and recurrence after treatment are the major problems of the current treatments. There are no clinical studies of use of Bimatoprost 0.03% in treatment of vitiligo, as it is supposed to cause more hyperpigmentation and hypertrichosis as compared to other topical prostaglandin analogues, hence, we decided to use it in treatment of localized vitiligo. Aim: In this study, twenty patients with vitiligo will be treated with topical Bimatoprost o.o3% ophthalmic solution for 4 months to elucidate its efficacy and tolerability in stable vitiligo. Patients and methods In this prospective, interventional, non-randomised, single blind, controlled study, twenty patients with stable vitiligo will be enrolled from the Dermatology out patient department of Gian Sagar Medical College and Hospital. The protocol will follow the Declaration of Helsinki and prior approval of Institutional Review Board will be obtained. Informed consent will be obtained from all patients. Detailed history and physical examination will be obtained. The age, sex, previous treatments, family history, type of vitiligo, durations of disease (in month), areas of involvement, Koebner phenomenon, leukotrichia will be recorded in special data sheet. The diagnosis of vitiligo will be made clinically. No concomitant treatment will be allowed and a washout period of at least 1 month will be given in patients using other therapies. Patients will be instructed to apply a Bimatoprost 0.03% solution twice daily to the depigmented skin taking care of no spillage to surrounding skin. The dimensions of the treated lesions will be measured in transverse and longitudinal axes at the time of enrollment, subsequently every month till 4 months. The measurement of the lesions will be performed by an independent observer who is blind to the treatment options. Photography will be done using a digital camera (Sony Digital Still Camera Cyber-shot ModelNO DSCF 717, Tokyo, Japan) at the baseline and at every follow up visit. Patients will be evaluated by the same observer who was blind to the treatment options. Primary Outcome Measures: The percentage of repigmentation in the previously depigmented patch, in form of color or size changes and folliculocentric repigmentation, of the treated and the control patches.6 Depending on the extent of repigmentation, the response to the treatment will be graded as: - no and minimal (<25%), - moderate (25-49%), - marked (50-74%), - excellent (75-99%), and - complete (100%) response. Response without reduction of the surface and only with perifollicular hyperpigmentation will be categorized as perifollicular pigmentation. Responding lesions will be defined as patches that achieved more than 50% repigmentation as compared with the baseline. Treatment will be discontinued if patients did not show any improvement or worsening at 2 months.
3 schema:endDate 2010-11-01T00:00:00Z
4 schema:keywords Dinoprostone
5 Japan
6 Langerhans cell
7 Medical College
8 PG
9 PGE-2
10 Prostaglandin F
11 Recurrence
12 Research Ethic Committee
13 Tokyo
14 Wound and Injury
15 active derivative
16 age
17 apoptotic process
18 appearance
19 approval
20 ax
21 baseline
22 calcineurin inhibitor
23 camera
24 care
25 cell-matrix adhesion
26 clinical study
27 color
28 considerable impact
29 control
30 controlled study
31 corticosteroid
32 cosmetic
33 current treatment
34 dark
35 data sheet
36 declaration
37 derivative
38 dermatology
39 diagnosis
40 different mechanism
41 digital camera
42 dimension
43 disappearance
44 disease
45 disorder
46 duration
47 effective and safe treatment
48 efficacy
49 enrollment
50 epidermal melanocyte
51 essential fatty acid
52 exact mechanism
53 experimental evidence
54 family history
55 glaucoma
56 histologic study
57 history
58 impaired function
59 improvement
60 induction
61 informed consent
62 involvement
63 iris
64 keratinocytes
65 lesion
66 major problem
67 measurement
68 mediated interaction
69 melanin
70 melanocyte
71 melanogenesis
72 membrane phospholipid
73 method
74 mouse skin
75 observer
76 patch
77 patient
78 phenomenon
79 photography
80 phototherapy
81 physical examination
82 physical symptom
83 pigmentation
84 population
85 possible mechanism
86 preliminary study
87 previous treatment
88 primary outcome measure
89 product
90 proliferation
91 prostaglandin
92 protocol
93 reduction
94 resistance
95 responsiveness
96 safety
97 scientific evidence
98 sex
99 signal
100 size change
101 skin
102 solution
103 spillage
104 stimulation
105 stimulus
106 surface
107 swollen
108 therapy
109 tolerability
110 topical agent
111 transverse
112 treatment complication
113 treatment modality
114 treatment option
115 ultraviolet radiation
116 vitiligo
117 vitro study
118 washout period
119 world
120 schema:name Efficacy and Safety of Topical Bimatoprost Solution 0.03% in Stable Vitiligo:A Preliminary Study
121 schema:sameAs https://app.dimensions.ai/details/clinical_trial/NCT01202513
122 schema:sdDatePublished 2019-03-07T15:23
123 schema:sdLicense https://scigraph.springernature.com/explorer/license/
124 schema:sdPublisher N24c9a38e5a014069b0a6997285b5ff86
125 schema:sponsor https://www.grid.ac/institutes/grid.464843.9
126 schema:startDate 2010-08-01T00:00:00Z
127 schema:subjectOf sg:pub.10.1111/1523-1747.ep12285717
128 sg:pub.10.1111/1523-1747.ep12471536
129 https://app.dimensions.ai/details/publication/pub.1074797281
130 https://doi.org/10.1002/jcp.1041420216
131 https://doi.org/10.1016/j.jaad.2004.02.028
132 https://doi.org/10.1034/j.1600-0749.2000.130305.x
133 schema:url https://clinicaltrials.gov/show/NCT01202513
134 sgo:license sg:explorer/license/
135 sgo:sdDataset clinical_trials
136 rdf:type schema:MedicalStudy
137 N24c9a38e5a014069b0a6997285b5ff86 schema:name Springer Nature - SN SciGraph project
138 rdf:type schema:Organization
139 anzsrc-for:3053 schema:inDefinedTermSet anzsrc-for:
140 rdf:type schema:DefinedTerm
141 sg:pub.10.1111/1523-1747.ep12285717 schema:sameAs https://app.dimensions.ai/details/publication/pub.1046751484
142 https://doi.org/10.1111/1523-1747.ep12285717
143 rdf:type schema:CreativeWork
144 sg:pub.10.1111/1523-1747.ep12471536 schema:sameAs https://app.dimensions.ai/details/publication/pub.1015013193
145 https://doi.org/10.1111/1523-1747.ep12471536
146 rdf:type schema:CreativeWork
147 https://app.dimensions.ai/details/publication/pub.1074797281 schema:CreativeWork
148 https://doi.org/10.1002/jcp.1041420216 schema:sameAs https://app.dimensions.ai/details/publication/pub.1004449106
149 rdf:type schema:CreativeWork
150 https://doi.org/10.1016/j.jaad.2004.02.028 schema:sameAs https://app.dimensions.ai/details/publication/pub.1039256867
151 rdf:type schema:CreativeWork
152 https://doi.org/10.1034/j.1600-0749.2000.130305.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1002467129
153 rdf:type schema:CreativeWork
154 https://www.grid.ac/institutes/grid.464843.9 schema:Organization
 




Preview window. Press ESC to close (or click here)


...